|
Age, y, median (range)
|
44.5 (14–74)
|
44 (15–67)
|
45 (14–74)
|
0.467
|
|
Gender (no.)
|
0.996
|
|
Male
|
61
|
24
|
37
| |
|
Female
|
35
|
13
|
20
| |
|
WBC count (×109/L), median (range)
|
13.3 (1.32–249.90)
|
26.99 (3.2–120.9)
|
9.20 (1.32–249.90)
|
0.160
|
|
Hemoglobin (g/L), median (range)
|
85.0 (34.90–136.00)
|
89.5 (55.0–136.0)
|
82.0 (34.9–125.0)
|
0.051
|
|
Platelet (×109/L), median (range)
|
38.0 (3.00–455.00)
|
38.5 (6.0–179.0)
|
36.0 (3.0–221.0)
|
0.975
|
|
Blasts in bone marrow (%), median (range)
|
65.0 (14.50–98.00)
|
71.0 (21.5–96)
|
60.1 (14.5–98.0)
|
0.038
|
|
Blasts in peripheral blood (/μL), median (range)
|
3730.7 (11.32–246,000)
|
4961.7 (479.9–124,900)
|
3730.7 (11.32–246,000)
|
0.035
|
|
FAB subtypes (no.)
|
0.229
|
|
M1
|
2
|
1
|
1
| |
|
M2
|
24
|
5
|
18
| |
|
M4
|
43
|
19
|
24
| |
|
M4Eo
|
2
|
2
|
0
| |
|
M5
|
19
|
7
|
11
| |
|
M6
|
1
|
1
|
0
| |
|
NA
|
5
|
2
|
3
| |
|
Cytogenetic-molecular risk group (no.)
|
0.045
|
|
Favorable
|
23
|
12
|
11
|
0.148
|
|
Intermediate
|
53
|
22
|
30
|
0.515
|
|
Unfavorable
|
20
|
3
|
16
|
0.019
|
|
LAIP (no.)
|
-
|
|
Cross-lineage antigen expression
|
63
|
29
|
34
| |
|
Asynchronous antigen expression
|
6
|
0
|
6
| |
|
Antigen dim/strong expression
|
13
|
6
|
6
| |
|
Antigen expression missing
|
8
|
4
|
3
| |
|
CR (%)
|
67 (69.79)
|
35 (94.6)
|
32 (56.1)
|
<0.001
|
|
MRD (+) (%)b
|
29 (55.77)
|
14 (50)
|
15 (62.5)
|
0.366
|
|
Relapse (%)
|
26 (32.50)
|
7 (19.44)
|
18 (42.86)
|
0.027
|
